KTTA KTTA
Company Profile ↓Company Overview
KTTA (KTTA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 3130.4% CAGR over the past five years.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +3130.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 3130.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3,130.37% |
| 1 Year: | 3,130.37% |
Stock Price Performance
| 1 Year: | -36.62% |
| 6 Months: | -46.43% |
| 3 Months: | -47.06% |
| 1 Month: | -13.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.10 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 3130.4% over 5 years.
CONS
- Trading 69.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 13.66K | 13.58K | 218.61K | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | 721 | -1.52K | 132.14K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -13.97K | -549.61K | -727.95K | -1.27M | -2.08M | -2.61M | -3.86M | -3.21M | -3.83M | -3.79M | -4.04M | -3.95M | -3.00M | -3.68M | -3.81M | -3.11M | -4.88M |
| Net Income | -13.97K | -549.61K | -727.95K | -1.53M | -1.57M | -2.66M | -4.59M | -3.54M | -3.76M | -3.61M | -3.86M | -3.87M | -3.00M | -3.56M | -3.72M | -3.04M | -2.87M |
| Diluted EPS | - | - | -0.09 | -0.17 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | 0.00 | -3.70 | -3.71 | -2.87 | -1.61 | -0.66 | -0.41 | -0.12 |
| R&D Expense | - | - | - | - | - | - | 1.28M | 1.10M | 2.03M | 1.62M | 1.75M | 2.36M | 1.58M | 1.73M | 2.15M | 1.36M | 2.94M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 15.06K | 486.56K | - | - | - |
| Gross Profit | -2.21K | - | - | - | - |
| Operating Income | -4.51M | -12.59M | -15.98M | -14.25M | -20.86M |
| Net Income | -2.17M | -13.94M | -15.96M | -13.90M | -20.43M |
| Diluted EPS | -0.21 | -1.76 | -0.42 | -12.69 | -2.91 |
| R&D Expense | - | 2.67M | 8.10M | 7.20M | 7.98M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 247.96K | 53.32M | 45.18M | 26.12M | 16.06M | 60.24M |
| Total Equity | 241.35K | 51.42M | 42.50M | 23.40M | 14.78M | 55.22M |
| Cash & Equivalents | 243.65K | 52.97M | 33.09M | 16.33M | 6.92M | 55.16M |
| Total Liabilities | 6.60K | 1.90M | 2.68M | 2.72M | 1.28M | 5.02M |
| Current Liabilities | 6.60K | 447.28K | 1.88M | 2.63M | 1.12M | 4.97M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -3.17M | -14.56M | - | -13.92M | -15.21M |
| Investing Cash Flow | -21.50K | -2.06M | - | - | 11.00K |
| Financing Cash Flow | 55.93M | -3.21M | - | 4.52M | 63.52M |
| Capital Expenditure | -21.50K | -107.10K | -34.30K | - | - |
| Free Cash Flow | -3.20M | -14.67M | - | - | - |
| Share Buybacks | - | - | 3.73M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | -14.7% | - | - | - | - |
| Operating Margin % | -29,925.7% | -2,587.3% | - | - | - |
| Net Margin % | -14,430.5% | -2,864.3% | - | - | - |
| ROE % | -4.2% | -32.8% | -68.2% | -94.1% | -37.0% |
| ROCE % | -8.5% | -29.1% | -68.0% | -95.4% | -37.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KTTA
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October 23, 2026 -- Full abs…
New Strong Buy Stocks for July 20th
KTTA, NTRS, YEXT, AEHR and STT have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 2026.
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
July 16 in Boston, management will engage with investors and industry participants at the healthcare-focused event covering neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology, and neuroimmunologyMIAMI, July 08, 2026 (G…
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
-- Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related events, and low rates of …
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
-- Remains on track to release interim NF1 data update in Q4 2026 ---- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Compa…
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting with Pasithea are encouraged to contact in adv…
KTTA — Frequently Asked Questions
What is the current share price of KTTA?
As of 2026-08-05 17:25 PDT, KTTA trades at $0.45 on NASDAQ/NYSE. Its 52-week range is $0.29 to $1.47.
What is the P/E ratio of KTTA?
KTTA trades at a trailing price-to-earnings (P/E) ratio of -0.15.
What is the return on equity (ROE) of KTTA?
KTTA has a return on equity (ROE) of -36.99%. Its return on capital employed (ROCE) is -37.74%.
Is KTTA a good stock to buy?
This page provides a data-driven analysis of KTTA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.